UroGen Pharma Ltd.

NasdaqGM:URGN 주식 리포트

시가총액: US$1.1b

UroGen Pharma 경영진

경영진 기준 점검 4/4

UroGen Pharma CEO는 Liz Barrett, Jan2019 에 임명되었습니다 의 임기는 7.33 년입니다. 총 연간 보상은 $4.15M, 19.9% 급여 및 80.1% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $7.51M 가치에 해당하는 회사 주식의 0.67% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 5.8 년과 7.3 년입니다.

핵심 정보

Liz Barrett

최고경영자

US$4.1m

총 보수

CEO 급여 비율19.90%
CEO 재임 기간7.3yrs
CEO 지분 보유율0.7%
경영진 평균 재임 기간5.8yrs
이사회 평균 재임 기간7.3yrs

최근 경영진 업데이트

Recent updates

URGN: Future Regulatory And Cost Setbacks Will Likely Restrain Upside Potential

Analysts have raised their price target on UroGen Pharma from $16.57 to $19.68 as updated assumptions for revenue growth, profit margins and a lower future P/E multiple align with a recently initiated bullish view on the stock. Analyst Commentary Recent research commentary on UroGen Pharma reflects a bullish initiation that aligns with the higher price target.

URGN: Future Profit Margins Will Improve Through LG UTUC Trial Momentum

Analysts have nudged their price target for UroGen Pharma higher to $36.11 from $35.63, reflecting updated assumptions around discount rates, revenue growth, profit margin, and future P/E following recent bullish Street research coverage. Analyst Commentary Recent Street research on UroGen Pharma has leaned constructive, which feeds into the modest uptick in the blended price target to $36.11.

URGN: Future Profit Margins Will Improve Through New J Code Reimbursement

Analysts have modestly fine-tuned their price target framework for UroGen Pharma, keeping fair value around $35.63. Small adjustments to the discount rate, revenue growth, profit margin, and forward P/E reflect updated assumptions rather than a major change in outlook.

URGN: Future Profit Margins Will Benefit From New J Code And Loan Refinancing

Analysts kept their fair value estimate for UroGen Pharma steady at $35.63 while making only minimal adjustments to assumptions around discount rate, revenue growth, profit margin, and future P/E. These changes reflect updated views on operating costs and financing conditions, similar to those that recently led to modest target reductions in other healthcare names.

URGN: Future Profit Margins Will Benefit From New J Code Reimbursement

Analysts now place UroGen Pharma's fair value at about $35.63, compared with the prior $35.25. This reflects updated assumptions around a slightly higher discount rate, modestly adjusted revenue growth and profit margin expectations, and a higher future P/E estimate.

UroGen Pharma Ltd. (NASDAQ:URGN) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Dec 05
UroGen Pharma Ltd. (NASDAQ:URGN) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

URGN: Future Profit Margins Will Benefit From Recent Regulatory Milestones

Analysts have raised their price target for UroGen Pharma from $33.75 to $35.25. They cite expectations of stronger revenue growth and improved profit margins as key drivers for the increase.

UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates

Nov 25

UroGen Pharma Ltd.'s (NASDAQ:URGN) Price Is Out Of Tune With Revenues

Oct 06
UroGen Pharma Ltd.'s (NASDAQ:URGN) Price Is Out Of Tune With Revenues

Office-Based Urology Therapies And Demographic Trends Will Redefine Care

Driven by an improved net profit margin and a modest reduction in future P/E, analysts have raised UroGen Pharma’s consensus price target from $32.00 to $33.75. What's in the News ZUSDURI (mitomycin) received FDA approval as the first and only approved therapy for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), with U.S. availability expected on or around July 1, 2025.

Office-Based Urology Therapies And Demographic Trends Will Redefine Care

As there is no change in the key metrics—consensus price target ($31.43), discount rate (6.85%), and future P/E (15.67x)—analyst valuation for UroGen Pharma remains steady, reflecting an unchanged fair value. What's in the News ZUSDURI (mitomycin) received FDA approval as the first and only medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), with U.S. availability expected on or around July 1, 2025.

The UroGen Pharma Ltd. (NASDAQ:URGN) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

Aug 10
The UroGen Pharma Ltd. (NASDAQ:URGN) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

Optimistic Investors Push UroGen Pharma Ltd. (NASDAQ:URGN) Shares Up 84% But Growth Is Lacking

Jul 07
Optimistic Investors Push UroGen Pharma Ltd. (NASDAQ:URGN) Shares Up 84% But Growth Is Lacking

Lacklustre Performance Is Driving UroGen Pharma Ltd.'s (NASDAQ:URGN) 30% Price Drop

May 17
Lacklustre Performance Is Driving UroGen Pharma Ltd.'s (NASDAQ:URGN) 30% Price Drop

Earnings Release: Here's Why Analysts Cut Their UroGen Pharma Ltd. (NASDAQ:URGN) Price Target To US$32.63

May 15
Earnings Release: Here's Why Analysts Cut Their UroGen Pharma Ltd. (NASDAQ:URGN) Price Target To US$32.63
User avatar

UGN-102 Approval Will Broaden Bladder Cancer Treatment Options

Anticipated approval of UGN-102 could significantly expand UroGen Pharma's market, boosting revenues with its compelling response rates and potential pricing power.

Improved Revenues Required Before UroGen Pharma Ltd. (NASDAQ:URGN) Shares Find Their Feet

Feb 12
Improved Revenues Required Before UroGen Pharma Ltd. (NASDAQ:URGN) Shares Find Their Feet

UroGen: Upcoming PDUFA, Some Concerns Remain

Jan 31

Is UroGen Pharma (NASDAQ:URGN) Weighed On By Its Debt Load?

Nov 18
Is UroGen Pharma (NASDAQ:URGN) Weighed On By Its Debt Load?

UroGen Pharma: There Is Some Potential Here

Aug 28

UroGen: Q3 NDA Opens Hefty Revenue Opportunity

Jun 17

UroGen Pharma Ltd.'s (NASDAQ:URGN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

Jun 14
UroGen Pharma Ltd.'s (NASDAQ:URGN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

Apr 09
UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

UroGen: All Eyes On UGN-102

Mar 18

UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Mar 17
UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Annual Results And Analysts Are Updating Their Estimates

UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive But Perhaps Not Attractive Enough

Jan 18
UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive But Perhaps Not Attractive Enough

CEO 보수 분석

Liz Barrett의 보수는 UroGen Pharma의 수익에 비해 어떻게 변했나요?
날짜총 보수급여회사 수익
Dec 31 2025n/an/a

-US$153m

Sep 30 2025n/an/a

-US$165m

Jun 30 2025n/an/a

-US$155m

Mar 31 2025n/an/a

-US$138m

Dec 31 2024US$4mUS$826k

-US$127m

Sep 30 2024n/an/a

-US$115m

Jun 30 2024n/an/a

-US$114m

Mar 31 2024n/an/a

-US$104m

Dec 31 2023US$5mUS$794k

-US$102m

Sep 30 2023n/an/a

-US$105m

Jun 30 2023n/an/a

-US$109m

Mar 31 2023n/an/a

-US$112m

Dec 31 2022US$2mUS$764k

-US$110m

Sep 30 2022n/an/a

-US$109m

Jun 30 2022n/an/a

-US$114m

Mar 31 2022n/an/a

-US$113m

Dec 31 2021US$4mUS$739k

-US$111m

Sep 30 2021n/an/a

-US$113m

Jun 30 2021n/an/a

-US$111m

Mar 31 2021n/an/a

-US$117m

Dec 31 2020US$2mUS$637k

-US$128m

Sep 30 2020n/an/a

-US$137m

Jun 30 2020n/an/a

-US$130m

Mar 31 2020n/an/a

-US$121m

Dec 31 2019US$26mUS$695k

-US$105m

보상 대 시장: Liz의 총 보수(USD4.15M)는 US 시장에서 비슷한 규모 기업의 평균(USD3.69M) 수준입니다.

보상과 수익: Liz의 보상은 지난 1년 동안 회사 실적과 일치했습니다.

CEO

Liz Barrett (63 yo)

7.3yrs
재임 기간
US$4,149,858
보수

Ms. Elizabeth A. Barrett, also known as Liz, has been President, Chief Executive Officer and Director of UroGen Pharma Ltd. since January 3, 2019. She has been a Director at Allogene Therapeutics, Inc. sin...

리더십 팀

이름직위재임 기간보수지분
Elizabeth Barrett
President7.3yrsUS$4.15m0.67%
$ 7.5m
Christopher Degnan
Chief Financial Officer1.6yrsUS$1.43m0.0047%
$ 52.4k
Jason Smith
General Counsel5.8yrsUS$1.28m0.11%
$ 1.2m
Vincent Perrone
Senior Director of Investor Relationsno data데이터 없음데이터 없음
Alison Hardgrove
Senior Vice President of Human Resourcesless than a year데이터 없음데이터 없음
Marina Konorty
Executive Vice President of Research & Development and Technical Operations6.2yrs데이터 없음데이터 없음
Mark Schoenberg
Chief Medical Officer8.4yrsUS$1.36m0.30%
$ 3.3m
James Ottinger
Executive Vice President of Regulatory Affairs & Quality6.2yrs데이터 없음데이터 없음
Michael Louie
Chief Development Officer2.8yrs데이터 없음데이터 없음
David Lin
Chief Commercial Officer1.9yrs데이터 없음데이터 없음
Timothy Simon
Senior Vice President of Business Development & Portfolio Strategyno data데이터 없음데이터 없음
Ron Bentsur
Advisorno dataUS$699.77k데이터 없음
5.8yrs
평균 재임 기간
59yo
평균 나이

경험이 풍부한 관리: URGN의 경영진은 노련하고 경험이 풍부합니다(평균 재임 5.8 년).

이사회 구성원

이름직위재임 기간보수지분
Elizabeth Barrett
President7.3yrsUS$4.15m0.67%
$ 7.5m
Cynthia Butitta
Independent Director8.6yrsUS$193.92k0.0041%
$ 46.0k
Stuart Holden
Independent Director10.4yrsUS$186.42k0.0041%
$ 46.0k
Arie Belldegrun
Independent Chairman13.4yrsUS$331.91k0.84%
$ 9.4m
Daniel Wildman
Independent Director3.5yrsUS$194.30k0.0041%
$ 46.0k
Jack Baniel
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Herbert Lepor
Chairman of Scientific Advisory Boardno data데이터 없음데이터 없음
Fred Witjes
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
James Robinson
Independent Director2.8yrsUS$183.92k0.0082%
$ 92.0k
Leana Wen
Independent Director3.8yrsUS$196.42k0.0041%
$ 46.0k
7.3yrs
평균 재임 기간
68yo
평균 나이

경험이 풍부한 이사회: URGN의 이사회는 경험이 있음으로 간주됩니다(평균 재임 7.3 년).

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/04 07:02
종가2026/05/04 00:00
수익2025/12/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

UroGen Pharma Ltd.는 21명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Anita DushyanthBerenberg
Jason KolbertD. Boral Capital LLC.
Paul ChoiGoldman Sachs